IL276286B2 - FC variants with improved binding to FCRN and extended half-life - Google Patents

FC variants with improved binding to FCRN and extended half-life

Info

Publication number
IL276286B2
IL276286B2 IL276286A IL27628620A IL276286B2 IL 276286 B2 IL276286 B2 IL 276286B2 IL 276286 A IL276286 A IL 276286A IL 27628620 A IL27628620 A IL 27628620A IL 276286 B2 IL276286 B2 IL 276286B2
Authority
IL
Israel
Prior art keywords
amino acid
acid position
tyrosine
binding polypeptide
domain
Prior art date
Application number
IL276286A
Other languages
English (en)
Hebrew (he)
Other versions
IL276286A (en
IL276286B1 (en
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65520379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL276286(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL276286A publication Critical patent/IL276286A/en
Publication of IL276286B1 publication Critical patent/IL276286B1/en
Publication of IL276286B2 publication Critical patent/IL276286B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL276286A 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life IL276286B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Publications (3)

Publication Number Publication Date
IL276286A IL276286A (en) 2020-09-30
IL276286B1 IL276286B1 (en) 2025-03-01
IL276286B2 true IL276286B2 (en) 2025-07-01

Family

ID=65520379

Family Applications (2)

Application Number Title Priority Date Filing Date
IL276286A IL276286B2 (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life
IL318916A IL318916A (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL318916A IL318916A (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life

Country Status (16)

Country Link
US (1) US20190263934A1 (enExample)
EP (1) EP3743441A1 (enExample)
JP (2) JP7399880B2 (enExample)
KR (2) KR102748986B1 (enExample)
CN (2) CN111788221A (enExample)
AU (2) AU2019212638B2 (enExample)
BR (1) BR112020015006A2 (enExample)
CA (1) CA3089602A1 (enExample)
CO (1) CO2020010269A2 (enExample)
IL (2) IL276286B2 (enExample)
MX (2) MX2020007882A (enExample)
MY (1) MY203898A (enExample)
PH (1) PH12020551134A1 (enExample)
SG (1) SG11202006905YA (enExample)
TW (1) TW201940512A (enExample)
WO (1) WO2019147973A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019212638B2 (en) * 2018-01-26 2025-04-03 Genzyme Corporation Fc variants with enhanced binding to FcRn and prolonged half-life
US20210024620A1 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
KR20230034954A (ko) * 2020-05-11 2023-03-10 인베티엑스 인코포레이티드 개에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
JP2023547239A (ja) * 2020-10-29 2023-11-09 フォーマイコン アーゲー Ａｃｅ２融合タンパク質及びその使用方法
IL308733A (en) 2021-05-27 2024-01-01 Sanofi Sa Fc variant with increased affinity for Fc receptors and improved thermal stability
US20250197514A1 (en) 2021-08-20 2025-06-19 Intervet Inc. ANTIBODIES AND IgG FUSION PROTEINS WITH AN EXTENDED HALF-LIFE
US20240409619A1 (en) * 2021-10-13 2024-12-12 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
EP4608859A1 (en) 2022-10-25 2025-09-03 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
CN120303299A (zh) 2022-12-05 2025-07-11 赛诺菲 转铁蛋白受体结合蛋白
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
EP0799244A1 (en) 1995-10-16 1997-10-08 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
KR101155191B1 (ko) * 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
ZA200701715B (en) * 2004-08-19 2008-07-30 Genentech Inc Polypeptide variants with altered effector function
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2373689A1 (en) * 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
JP5944831B2 (ja) * 2009-12-23 2016-07-05 シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ 抗ｆｌｔ３抗体及びその使用方法
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
KR102266819B1 (ko) * 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
BR112017006178A2 (pt) * 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
IL315729A (en) * 2016-08-02 2024-11-01 Visterra Inc Fc region containing polypeptides and uses thereof
AU2019212638B2 (en) * 2018-01-26 2025-04-03 Genzyme Corporation Fc variants with enhanced binding to FcRn and prolonged half-life

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子

Also Published As

Publication number Publication date
KR20250008975A (ko) 2025-01-16
PH12020551134A1 (en) 2021-05-31
JP7399880B2 (ja) 2023-12-18
AU2019212638A1 (en) 2020-09-17
IL318916A (en) 2025-04-01
JP2024026255A (ja) 2024-02-28
TW201940512A (zh) 2019-10-16
US20190263934A1 (en) 2019-08-29
EP3743441A1 (en) 2020-12-02
CA3089602A1 (en) 2019-08-01
IL276286A (en) 2020-09-30
JP2021511830A (ja) 2021-05-13
IL276286B1 (en) 2025-03-01
MX2020007882A (es) 2020-12-03
RU2020128177A (ru) 2022-02-28
WO2019147973A1 (en) 2019-08-01
AU2025204826A1 (en) 2025-07-17
MX2025009543A (es) 2025-09-02
KR20200115568A (ko) 2020-10-07
MY203898A (en) 2024-07-23
SG11202006905YA (en) 2020-08-28
KR102748986B1 (ko) 2025-01-02
AU2019212638B2 (en) 2025-04-03
CN111788221A (zh) 2020-10-16
NZ767453A (en) 2025-03-28
CN119350481A (zh) 2025-01-24
BR112020015006A2 (pt) 2020-12-29
CO2020010269A2 (es) 2020-12-10

Similar Documents

Publication Publication Date Title
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
JP2024026255A5 (enExample)
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
CN110382529B (zh) 工程化的异源二聚体蛋白质
CN111971301B (zh) 抗ms4a4a抗体及其使用方法
JP2012515556A5 (enExample)
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
JP2022025063A (ja) 抗バリアントＦｃ領域抗体および使用法
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
CA2502904A1 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TR201808458T4 (tr) FC-reseptör bazlı afinite kromatografisi.
CN113227134A (zh) 抗体的Fc区变体
EP3041865A2 (en) Readily isolated bispecific binding molecules with native format having mutated constant regions
EP2773660A2 (en) Chimeric human-camel antigens and their use
KR20180034500A (ko) 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
TW201716442A (zh) 抗EphA4抗體
TW202233694A (zh) 雙特異性抗體
CN111491951A (zh) 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
US20250266122A1 (en) Multi-domain proteins with increased native state colloidal stability
EP3615678A1 (en) Antibody selection method
JPWO2019147973A5 (enExample)
WO2022117065A1 (zh) 多特异性抗原结合蛋白
CN112513074A (zh) 生产两种或更多种不同抗体的受控混合物的方法
CN112703204B (zh) 针对可溶性bcma的抗体
KR20150134319A (ko) 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편